Abiopharma

🔍 Matly David (Executive)

Company: Inhibrx Biosciences, Inc. (INBX)

Report Date: 2026-04-24

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Stock Option (right to buy) at $129.06 per share (Derivative)
  Date: 2026-04-24 | Code: A | Expires: 2036-04-24 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on April 24, 2027, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.